Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://xiaomi.eu
Are you over 18 and want to see adult content?
A complete backup of https://tribute.ca
Are you over 18 and want to see adult content?
A complete backup of https://epubli.de
Are you over 18 and want to see adult content?
A complete backup of https://topcropmanager.com
Are you over 18 and want to see adult content?
A complete backup of https://musika-orchestra.com
Are you over 18 and want to see adult content?
A complete backup of https://chill.ie
Are you over 18 and want to see adult content?
A complete backup of https://cattlesales.com.au
Are you over 18 and want to see adult content?
A complete backup of https://moyaokruga.ru
Are you over 18 and want to see adult content?
A complete backup of https://bfranklincrafts.com
Are you over 18 and want to see adult content?
A complete backup of https://museoblaisten.com
Are you over 18 and want to see adult content?
A complete backup of https://visitfinland.fi
Are you over 18 and want to see adult content?
A complete backup of https://wintercoatstore.site
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://madhavchetan.com
Are you over 18 and want to see adult content?
A complete backup of https://sumome.com
Are you over 18 and want to see adult content?
A complete backup of https://volcanowinery.com
Are you over 18 and want to see adult content?
A complete backup of https://wildliferanchtexas.com
Are you over 18 and want to see adult content?
A complete backup of https://musicpage.com
Are you over 18 and want to see adult content?
A complete backup of https://drumlitmag.com
Are you over 18 and want to see adult content?
A complete backup of https://help-wifi.com
Are you over 18 and want to see adult content?
A complete backup of https://andasconceptnetwork.net
Are you over 18 and want to see adult content?
A complete backup of https://mystikmedia.com
Are you over 18 and want to see adult content?
A complete backup of https://baby-chick.com
Are you over 18 and want to see adult content?
A complete backup of https://schrts.co
Are you over 18 and want to see adult content?
Text
battle
VCROI 2021 RESOURCES On-Demand Webcasts. Full and free access to all virtual CROI 2021 on-demand session recordings are now available. CME for viewing the on-demand webcasts is only available to all registered virtual CROI 2021 attendees. The deadline to claim CME credits, ABIM MOC points, or certificate of participation is May 12. View Webcasts. VCROI 2021 ABSTRACT EBOOK NOW AVAILABLE FOR PUBLIC ACCESS The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
REDUCTION IN INFECTIOUS SARS-COV-2 IN TREATMENT STUDY … Subsequently, in the dose-range finding portion of the study, participants were randomized in a 3:1 ratio to receive 200, 400, or 800 mg molnupiravir or placebo twice daily for 5 days. Nasopharyngeal swabs were analyzed from 175 subjects at enrollment, Day 3, and Day 5 for SARS-CoV-2 infectivity. Samples were stored at 4°C for up to 72hours
BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND … The COVID-19 pandemic has disproportionately affected residents of skilled nursing and assisted living facilities. Interventions are urgently needed to protect this vulnerable population. Bamlanivimab is a potent neutralizing monoclonal antibody that binds the receptor-binding domain of the spike protein of SARS-CoV-2. This study evaluates the safety and efficacy of bamlanivimab in preventing WEIGHT GAIN DURING TREATMENT AMONG 3,468 TREATMENT Weight gain is a known complication of HIV treatment. However, the specific risk factors and magnitude are not well understood, especially after the initial treatment period. The objectives of this study were (1) to describe the demographic, clinical, and treatment characteristics of treatment-experienced adults with virally-suppressed HIV that had ≥3% annual weight gain in recentJOHN M. COFFIN, PHD
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
BILIRUBIN AS A SURROGATE MARKER OF DOLUTEGRAVIR … In Phase 3 trials, dolutegravir (DTG) was well tolerated, with only 2% prevalence of adverse events (AE) leading to discontinuation. However, in post-marketing data, use of DTG has been associated with central nervous system (CNS) events. Higher DTG plasma levels have previously been associated with CNS AE. Given that both DTG and bilirubin (BIL)are
144-WEEK EFFICACY AND SAFETY OF B/F/TAF IN TREATMENT … As people living with HIV age, identifying effective and safe regimens for older individuals is of heightened importance. The single-tablet regimen bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) may benefit older adults due to its favorable adverse event (AE) profile and few drug interactions. We conducted two randomized, double blind, phase 3 studies of B/F/TAF in treatment CONCENTRATIONS OF TFV AND TFVDP IN FEMALE MUCOSAL TISSUES The administration of oral tenofovir disoproxil fumarate (TDF) results in 100-fold higher exposure of tenofovir (TFV) and its active moiety, tenofovir diphosphate (TFVdp), in colorectal tissues compared to female genital tract tissues. This may contribute to PrEP adherence forgiveness in MSM compared to women. Tenofovir alafenamide (TAF), a novel TFV prodrug, achieves higher concentrations of CROI CONFERENCEABOUT CROIPRESENTERSATTENDEESSCHOLARSHIPSRESOURCESMEDIA The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
VCROI 2021 RESOURCES On-Demand Webcasts. Full and free access to all virtual CROI 2021 on-demand session recordings are now available. CME for viewing the on-demand webcasts is only available to all registered virtual CROI 2021 attendees. The deadline to claim CME credits, ABIM MOC points, or certificate of participation is May 12. View Webcasts. VCROI 2021 ABSTRACT EBOOK NOW AVAILABLE FOR PUBLIC ACCESS The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
REDUCTION IN INFECTIOUS SARS-COV-2 IN TREATMENT STUDY … Subsequently, in the dose-range finding portion of the study, participants were randomized in a 3:1 ratio to receive 200, 400, or 800 mg molnupiravir or placebo twice daily for 5 days. Nasopharyngeal swabs were analyzed from 175 subjects at enrollment, Day 3, and Day 5 for SARS-CoV-2 infectivity. Samples were stored at 4°C for up to 72hours
BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND … The COVID-19 pandemic has disproportionately affected residents of skilled nursing and assisted living facilities. Interventions are urgently needed to protect this vulnerable population. Bamlanivimab is a potent neutralizing monoclonal antibody that binds the receptor-binding domain of the spike protein of SARS-CoV-2. This study evaluates the safety and efficacy of bamlanivimab in preventing WEIGHT GAIN DURING TREATMENT AMONG 3,468 TREATMENT Weight gain is a known complication of HIV treatment. However, the specific risk factors and magnitude are not well understood, especially after the initial treatment period. The objectives of this study were (1) to describe the demographic, clinical, and treatment characteristics of treatment-experienced adults with virally-suppressed HIV that had ≥3% annual weight gain in recentJOHN M. COFFIN, PHD
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
BILIRUBIN AS A SURROGATE MARKER OF DOLUTEGRAVIR … In Phase 3 trials, dolutegravir (DTG) was well tolerated, with only 2% prevalence of adverse events (AE) leading to discontinuation. However, in post-marketing data, use of DTG has been associated with central nervous system (CNS) events. Higher DTG plasma levels have previously been associated with CNS AE. Given that both DTG and bilirubin (BIL)are
144-WEEK EFFICACY AND SAFETY OF B/F/TAF IN TREATMENT … As people living with HIV age, identifying effective and safe regimens for older individuals is of heightened importance. The single-tablet regimen bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) may benefit older adults due to its favorable adverse event (AE) profile and few drug interactions. We conducted two randomized, double blind, phase 3 studies of B/F/TAF in treatment CONCENTRATIONS OF TFV AND TFVDP IN FEMALE MUCOSAL TISSUES The administration of oral tenofovir disoproxil fumarate (TDF) results in 100-fold higher exposure of tenofovir (TFV) and its active moiety, tenofovir diphosphate (TFVdp), in colorectal tissues compared to female genital tract tissues. This may contribute to PrEP adherence forgiveness in MSM compared to women. Tenofovir alafenamide (TAF), a novel TFV prodrug, achieves higher concentrations ofCROI 2020
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
REDUCTION IN INFECTIOUS SARS-COV-2 IN TREATMENT STUDY … Subsequently, in the dose-range finding portion of the study, participants were randomized in a 3:1 ratio to receive 200, 400, or 800 mg molnupiravir or placebo twice daily for 5 days. Nasopharyngeal swabs were analyzed from 175 subjects at enrollment, Day 3, and Day 5 for SARS-CoV-2 infectivity. Samples were stored at 4°C for up to 72hours
BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN … Patients with underlying medical conditions have a greater risk of developing severe COVID-19. Unlike vaccine-derived immunity which develops over time, administration of neutralizing monoclonal antibodies is an immediate, passive humoral immunotherapy, with the potential to reduce disease progression, emergency room visits, hospitalizations, and death. In this phase 3 portion of the BLAZE-1REGISTRATION
Registration. Registration for vCROI 2021 is now closed. Registered participants will have access to the Virtual Platform, playback of live sessions, on-demand sessions, and networking features, including Q&A and Chat features where speakers can address questions directly, until April 9, 2021. Full and free access begins on April 15, 2021 for MEDIA ACCREDITATION AND REGISTRATION Media accreditation for CROI 2021 opens on January 4, 2021, and closes on February 26, 2021. All media registration must be completed by March 3, 2021. There is no on-site registration for the conference. CROI is a scientific research meeting. Media registration is reserved for journalists with demonstrated experience covering basic andJOHN M. COFFIN, PHD
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
MODELING-SUPPORTED ISLATRAVIR DOSE SELECTION FOR … Islatravir (ISL) is the first nucleoside reverse transcriptase translocation inhibitor (NRTTI) in development for the treatment and prevention of HIV-1 infection. Single doses of ISL as low as 0.5 mg showed robust efficacy in a proof-of-concept (POC) clinical trial and established an IQ (ratio of drug exposure to potency) of 5 for ISL forwild-type
A PHASE I DOSE-ESCALATION STUDY OF MONOCLONAL ANTIBODY Human monoclonal antibodies that potently and broadly neutralize HIV-1 (bnMAbs) are under development for prevention and treatment of HIV-1 infection. The VRC01 class of bnMAbs targets the CD4-binding site of the HIV-1 envelope protein. VRC01, the first member of this antibody class, is currently being evaluated for prevention of HIV infection intwo phase 2b
NO SIGNIFICANT CHANGE ON RESERVOIR IN QUATUOR: A 4/7 … ANRS 170 QUATUOR study demonstrated the non-inferiority of a 4/7 days maintenance strategy vs a 7/7 days regimen in patients with controlled viral load (VL) under triple therapy with either PI, NNRTI, or InSTI based regimen at week 48 (W48). The aims of these virological sub-studies were to assess HIV cellular reservoir size, HIV residual COMPARING CARDIOVASCULAR DISEASE RISK SCORES FOR USE IN While cardiovascular disease (CVD) risk stratification tools exist for use in the general population, they may not accurately estimate risk in persons living with HIV (PLWH). Examining the performance of CVD risk scores in PLWH requires large studies with comprehensive clinical data and well-validated outcomes. We developed a state-of-the-art screening algorithm and central adjudication CROI CONFERENCEABOUT CROIPRESENTERSATTENDEESSCHOLARSHIPSRESOURCESMEDIA The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
VCROI 2021 RESOURCES On-Demand Webcasts. Full and free access to all virtual CROI 2021 on-demand session recordings are now available. CME for viewing the on-demand webcasts is only available to all registered virtual CROI 2021 attendees. The deadline to claim CME credits, ABIM MOC points, or certificate of participation is May 12. View Webcasts. VCROI 2021 ABSTRACT EBOOK NOW AVAILABLE FOR PUBLIC ACCESS The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
REDUCTION IN INFECTIOUS SARS-COV-2 IN TREATMENT STUDY … Subsequently, in the dose-range finding portion of the study, participants were randomized in a 3:1 ratio to receive 200, 400, or 800 mg molnupiravir or placebo twice daily for 5 days. Nasopharyngeal swabs were analyzed from 175 subjects at enrollment, Day 3, and Day 5 for SARS-CoV-2 infectivity. Samples were stored at 4°C for up to 72hours
BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND … The COVID-19 pandemic has disproportionately affected residents of skilled nursing and assisted living facilities. Interventions are urgently needed to protect this vulnerable population. Bamlanivimab is a potent neutralizing monoclonal antibody that binds the receptor-binding domain of the spike protein of SARS-CoV-2. This study evaluates the safety and efficacy of bamlanivimab in preventing WEIGHT GAIN DURING TREATMENT AMONG 3,468 TREATMENT Weight gain is a known complication of HIV treatment. However, the specific risk factors and magnitude are not well understood, especially after the initial treatment period. The objectives of this study were (1) to describe the demographic, clinical, and treatment characteristics of treatment-experienced adults with virally-suppressed HIV that had ≥3% annual weight gain in recentJOHN M. COFFIN, PHD
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
BILIRUBIN AS A SURROGATE MARKER OF DOLUTEGRAVIR … In Phase 3 trials, dolutegravir (DTG) was well tolerated, with only 2% prevalence of adverse events (AE) leading to discontinuation. However, in post-marketing data, use of DTG has been associated with central nervous system (CNS) events. Higher DTG plasma levels have previously been associated with CNS AE. Given that both DTG and bilirubin (BIL)are
144-WEEK EFFICACY AND SAFETY OF B/F/TAF IN TREATMENT … As people living with HIV age, identifying effective and safe regimens for older individuals is of heightened importance. The single-tablet regimen bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) may benefit older adults due to its favorable adverse event (AE) profile and few drug interactions. We conducted two randomized, double blind, phase 3 studies of B/F/TAF in treatment CONCENTRATIONS OF TFV AND TFVDP IN FEMALE MUCOSAL TISSUES The administration of oral tenofovir disoproxil fumarate (TDF) results in 100-fold higher exposure of tenofovir (TFV) and its active moiety, tenofovir diphosphate (TFVdp), in colorectal tissues compared to female genital tract tissues. This may contribute to PrEP adherence forgiveness in MSM compared to women. Tenofovir alafenamide (TAF), a novel TFV prodrug, achieves higher concentrations of CROI CONFERENCEABOUT CROIPRESENTERSATTENDEESSCHOLARSHIPSRESOURCESMEDIA The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
VCROI 2021 RESOURCES On-Demand Webcasts. Full and free access to all virtual CROI 2021 on-demand session recordings are now available. CME for viewing the on-demand webcasts is only available to all registered virtual CROI 2021 attendees. The deadline to claim CME credits, ABIM MOC points, or certificate of participation is May 12. View Webcasts. VCROI 2021 ABSTRACT EBOOK NOW AVAILABLE FOR PUBLIC ACCESS The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
REDUCTION IN INFECTIOUS SARS-COV-2 IN TREATMENT STUDY … Subsequently, in the dose-range finding portion of the study, participants were randomized in a 3:1 ratio to receive 200, 400, or 800 mg molnupiravir or placebo twice daily for 5 days. Nasopharyngeal swabs were analyzed from 175 subjects at enrollment, Day 3, and Day 5 for SARS-CoV-2 infectivity. Samples were stored at 4°C for up to 72hours
BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND … The COVID-19 pandemic has disproportionately affected residents of skilled nursing and assisted living facilities. Interventions are urgently needed to protect this vulnerable population. Bamlanivimab is a potent neutralizing monoclonal antibody that binds the receptor-binding domain of the spike protein of SARS-CoV-2. This study evaluates the safety and efficacy of bamlanivimab in preventing WEIGHT GAIN DURING TREATMENT AMONG 3,468 TREATMENT Weight gain is a known complication of HIV treatment. However, the specific risk factors and magnitude are not well understood, especially after the initial treatment period. The objectives of this study were (1) to describe the demographic, clinical, and treatment characteristics of treatment-experienced adults with virally-suppressed HIV that had ≥3% annual weight gain in recentJOHN M. COFFIN, PHD
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
BILIRUBIN AS A SURROGATE MARKER OF DOLUTEGRAVIR … In Phase 3 trials, dolutegravir (DTG) was well tolerated, with only 2% prevalence of adverse events (AE) leading to discontinuation. However, in post-marketing data, use of DTG has been associated with central nervous system (CNS) events. Higher DTG plasma levels have previously been associated with CNS AE. Given that both DTG and bilirubin (BIL)are
144-WEEK EFFICACY AND SAFETY OF B/F/TAF IN TREATMENT … As people living with HIV age, identifying effective and safe regimens for older individuals is of heightened importance. The single-tablet regimen bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) may benefit older adults due to its favorable adverse event (AE) profile and few drug interactions. We conducted two randomized, double blind, phase 3 studies of B/F/TAF in treatment CONCENTRATIONS OF TFV AND TFVDP IN FEMALE MUCOSAL TISSUES The administration of oral tenofovir disoproxil fumarate (TDF) results in 100-fold higher exposure of tenofovir (TFV) and its active moiety, tenofovir diphosphate (TFVdp), in colorectal tissues compared to female genital tract tissues. This may contribute to PrEP adherence forgiveness in MSM compared to women. Tenofovir alafenamide (TAF), a novel TFV prodrug, achieves higher concentrations ofCROI 2020
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
REDUCTION IN INFECTIOUS SARS-COV-2 IN TREATMENT STUDY … Subsequently, in the dose-range finding portion of the study, participants were randomized in a 3:1 ratio to receive 200, 400, or 800 mg molnupiravir or placebo twice daily for 5 days. Nasopharyngeal swabs were analyzed from 175 subjects at enrollment, Day 3, and Day 5 for SARS-CoV-2 infectivity. Samples were stored at 4°C for up to 72hours
BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN … Patients with underlying medical conditions have a greater risk of developing severe COVID-19. Unlike vaccine-derived immunity which develops over time, administration of neutralizing monoclonal antibodies is an immediate, passive humoral immunotherapy, with the potential to reduce disease progression, emergency room visits, hospitalizations, and death. In this phase 3 portion of the BLAZE-1REGISTRATION
Registration. Registration for vCROI 2021 is now closed. Registered participants will have access to the Virtual Platform, playback of live sessions, on-demand sessions, and networking features, including Q&A and Chat features where speakers can address questions directly, until April 9, 2021. Full and free access begins on April 15, 2021 for MEDIA ACCREDITATION AND REGISTRATION Media accreditation for CROI 2021 opens on January 4, 2021, and closes on February 26, 2021. All media registration must be completed by March 3, 2021. There is no on-site registration for the conference. CROI is a scientific research meeting. Media registration is reserved for journalists with demonstrated experience covering basic andJOHN M. COFFIN, PHD
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
MODELING-SUPPORTED ISLATRAVIR DOSE SELECTION FOR … Islatravir (ISL) is the first nucleoside reverse transcriptase translocation inhibitor (NRTTI) in development for the treatment and prevention of HIV-1 infection. Single doses of ISL as low as 0.5 mg showed robust efficacy in a proof-of-concept (POC) clinical trial and established an IQ (ratio of drug exposure to potency) of 5 for ISL forwild-type
A PHASE I DOSE-ESCALATION STUDY OF MONOCLONAL ANTIBODY Human monoclonal antibodies that potently and broadly neutralize HIV-1 (bnMAbs) are under development for prevention and treatment of HIV-1 infection. The VRC01 class of bnMAbs targets the CD4-binding site of the HIV-1 envelope protein. VRC01, the first member of this antibody class, is currently being evaluated for prevention of HIV infection intwo phase 2b
NO SIGNIFICANT CHANGE ON RESERVOIR IN QUATUOR: A 4/7 … ANRS 170 QUATUOR study demonstrated the non-inferiority of a 4/7 days maintenance strategy vs a 7/7 days regimen in patients with controlled viral load (VL) under triple therapy with either PI, NNRTI, or InSTI based regimen at week 48 (W48). The aims of these virological sub-studies were to assess HIV cellular reservoir size, HIV residual COMPARING CARDIOVASCULAR DISEASE RISK SCORES FOR USE IN While cardiovascular disease (CVD) risk stratification tools exist for use in the general population, they may not accurately estimate risk in persons living with HIV (PLWH). Examining the performance of CVD risk scores in PLWH requires large studies with comprehensive clinical data and well-validated outcomes. We developed a state-of-the-art screening algorithm and central adjudication CROI CONFERENCEABOUT CROIPRESENTERSATTENDEESSCHOLARSHIPSRESOURCESMEDIA The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
VCROI 2021 RESOURCES On-Demand Webcasts. Full and free access to all virtual CROI 2021 on-demand session recordings are now available. CME for viewing the on-demand webcasts is only available to all registered virtual CROI 2021 attendees. The deadline to claim CME credits, ABIM MOC points, or certificate of participation is May 12. View Webcasts. VCROI 2021 ABSTRACT EBOOK NOW AVAILABLE FOR PUBLIC ACCESS The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
REDUCTION IN INFECTIOUS SARS-COV-2 IN TREATMENT STUDY … Subsequently, in the dose-range finding portion of the study, participants were randomized in a 3:1 ratio to receive 200, 400, or 800 mg molnupiravir or placebo twice daily for 5 days. Nasopharyngeal swabs were analyzed from 175 subjects at enrollment, Day 3, and Day 5 for SARS-CoV-2 infectivity. Samples were stored at 4°C for up to 72hours
BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND … The COVID-19 pandemic has disproportionately affected residents of skilled nursing and assisted living facilities. Interventions are urgently needed to protect this vulnerable population. Bamlanivimab is a potent neutralizing monoclonal antibody that binds the receptor-binding domain of the spike protein of SARS-CoV-2. This study evaluates the safety and efficacy of bamlanivimab in preventing WEIGHT GAIN DURING TREATMENT AMONG 3,468 TREATMENT Weight gain is a known complication of HIV treatment. However, the specific risk factors and magnitude are not well understood, especially after the initial treatment period. The objectives of this study were (1) to describe the demographic, clinical, and treatment characteristics of treatment-experienced adults with virally-suppressed HIV that had ≥3% annual weight gain in recentJOHN M. COFFIN, PHD
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
BILIRUBIN AS A SURROGATE MARKER OF DOLUTEGRAVIR … In Phase 3 trials, dolutegravir (DTG) was well tolerated, with only 2% prevalence of adverse events (AE) leading to discontinuation. However, in post-marketing data, use of DTG has been associated with central nervous system (CNS) events. Higher DTG plasma levels have previously been associated with CNS AE. Given that both DTG and bilirubin (BIL)are
144-WEEK EFFICACY AND SAFETY OF B/F/TAF IN TREATMENT … As people living with HIV age, identifying effective and safe regimens for older individuals is of heightened importance. The single-tablet regimen bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) may benefit older adults due to its favorable adverse event (AE) profile and few drug interactions. We conducted two randomized, double blind, phase 3 studies of B/F/TAF in treatment CONCENTRATIONS OF TFV AND TFVDP IN FEMALE MUCOSAL TISSUES The administration of oral tenofovir disoproxil fumarate (TDF) results in 100-fold higher exposure of tenofovir (TFV) and its active moiety, tenofovir diphosphate (TFVdp), in colorectal tissues compared to female genital tract tissues. This may contribute to PrEP adherence forgiveness in MSM compared to women. Tenofovir alafenamide (TAF), a novel TFV prodrug, achieves higher concentrations of CROI CONFERENCEABOUT CROIPRESENTERSATTENDEESSCHOLARSHIPSRESOURCESMEDIA The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
VCROI 2021 RESOURCES On-Demand Webcasts. Full and free access to all virtual CROI 2021 on-demand session recordings are now available. CME for viewing the on-demand webcasts is only available to all registered virtual CROI 2021 attendees. The deadline to claim CME credits, ABIM MOC points, or certificate of participation is May 12. View Webcasts. VCROI 2021 ABSTRACT EBOOK NOW AVAILABLE FOR PUBLIC ACCESS The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
REDUCTION IN INFECTIOUS SARS-COV-2 IN TREATMENT STUDY … Subsequently, in the dose-range finding portion of the study, participants were randomized in a 3:1 ratio to receive 200, 400, or 800 mg molnupiravir or placebo twice daily for 5 days. Nasopharyngeal swabs were analyzed from 175 subjects at enrollment, Day 3, and Day 5 for SARS-CoV-2 infectivity. Samples were stored at 4°C for up to 72hours
BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND … The COVID-19 pandemic has disproportionately affected residents of skilled nursing and assisted living facilities. Interventions are urgently needed to protect this vulnerable population. Bamlanivimab is a potent neutralizing monoclonal antibody that binds the receptor-binding domain of the spike protein of SARS-CoV-2. This study evaluates the safety and efficacy of bamlanivimab in preventing WEIGHT GAIN DURING TREATMENT AMONG 3,468 TREATMENT Weight gain is a known complication of HIV treatment. However, the specific risk factors and magnitude are not well understood, especially after the initial treatment period. The objectives of this study were (1) to describe the demographic, clinical, and treatment characteristics of treatment-experienced adults with virally-suppressed HIV that had ≥3% annual weight gain in recentJOHN M. COFFIN, PHD
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
BILIRUBIN AS A SURROGATE MARKER OF DOLUTEGRAVIR … In Phase 3 trials, dolutegravir (DTG) was well tolerated, with only 2% prevalence of adverse events (AE) leading to discontinuation. However, in post-marketing data, use of DTG has been associated with central nervous system (CNS) events. Higher DTG plasma levels have previously been associated with CNS AE. Given that both DTG and bilirubin (BIL)are
144-WEEK EFFICACY AND SAFETY OF B/F/TAF IN TREATMENT … As people living with HIV age, identifying effective and safe regimens for older individuals is of heightened importance. The single-tablet regimen bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) may benefit older adults due to its favorable adverse event (AE) profile and few drug interactions. We conducted two randomized, double blind, phase 3 studies of B/F/TAF in treatment CONCENTRATIONS OF TFV AND TFVDP IN FEMALE MUCOSAL TISSUES The administration of oral tenofovir disoproxil fumarate (TDF) results in 100-fold higher exposure of tenofovir (TFV) and its active moiety, tenofovir diphosphate (TFVdp), in colorectal tissues compared to female genital tract tissues. This may contribute to PrEP adherence forgiveness in MSM compared to women. Tenofovir alafenamide (TAF), a novel TFV prodrug, achieves higher concentrations ofCROI 2020
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
REDUCTION IN INFECTIOUS SARS-COV-2 IN TREATMENT STUDY … Subsequently, in the dose-range finding portion of the study, participants were randomized in a 3:1 ratio to receive 200, 400, or 800 mg molnupiravir or placebo twice daily for 5 days. Nasopharyngeal swabs were analyzed from 175 subjects at enrollment, Day 3, and Day 5 for SARS-CoV-2 infectivity. Samples were stored at 4°C for up to 72hours
BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN … Patients with underlying medical conditions have a greater risk of developing severe COVID-19. Unlike vaccine-derived immunity which develops over time, administration of neutralizing monoclonal antibodies is an immediate, passive humoral immunotherapy, with the potential to reduce disease progression, emergency room visits, hospitalizations, and death. In this phase 3 portion of the BLAZE-1REGISTRATION
Registration. Registration for vCROI 2021 is now closed. Registered participants will have access to the Virtual Platform, playback of live sessions, on-demand sessions, and networking features, including Q&A and Chat features where speakers can address questions directly, until April 9, 2021. Full and free access begins on April 15, 2021 for MEDIA ACCREDITATION AND REGISTRATION Media accreditation for CROI 2021 opens on January 4, 2021, and closes on February 26, 2021. All media registration must be completed by March 3, 2021. There is no on-site registration for the conference. CROI is a scientific research meeting. Media registration is reserved for journalists with demonstrated experience covering basic andJOHN M. COFFIN, PHD
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoingbattle
MODELING-SUPPORTED ISLATRAVIR DOSE SELECTION FOR … Islatravir (ISL) is the first nucleoside reverse transcriptase translocation inhibitor (NRTTI) in development for the treatment and prevention of HIV-1 infection. Single doses of ISL as low as 0.5 mg showed robust efficacy in a proof-of-concept (POC) clinical trial and established an IQ (ratio of drug exposure to potency) of 5 for ISL forwild-type
A PHASE I DOSE-ESCALATION STUDY OF MONOCLONAL ANTIBODY Human monoclonal antibodies that potently and broadly neutralize HIV-1 (bnMAbs) are under development for prevention and treatment of HIV-1 infection. The VRC01 class of bnMAbs targets the CD4-binding site of the HIV-1 envelope protein. VRC01, the first member of this antibody class, is currently being evaluated for prevention of HIV infection intwo phase 2b
NO SIGNIFICANT CHANGE ON RESERVOIR IN QUATUOR: A 4/7 … ANRS 170 QUATUOR study demonstrated the non-inferiority of a 4/7 days maintenance strategy vs a 7/7 days regimen in patients with controlled viral load (VL) under triple therapy with either PI, NNRTI, or InSTI based regimen at week 48 (W48). The aims of these virological sub-studies were to assess HIV cellular reservoir size, HIV residual COMPARING CARDIOVASCULAR DISEASE RISK SCORES FOR USE IN While cardiovascular disease (CVD) risk stratification tools exist for use in the general population, they may not accurately estimate risk in persons living with HIV (PLWH). Examining the performance of CVD risk scores in PLWH requires large studies with comprehensive clinical data and well-validated outcomes. We developed a state-of-the-art screening algorithm and central adjudicationSkip to content
__Login
Search: __
CROI Conference
* About CROI __
* Important Dates and Deadlines* Future CROI
* CROI Foundation
* Scientific Program Committee * Community Liaison Subcommittee* IAS-USA
* Commercial Support * Website Policies and Copyright * HIV Virus Illustration* Contact Us
* Presenters __
* Abstract Submission * CROI 2021 Abstract Categories * Oral Abstract Presenters * Science Spotlight Presenters * Invited Presenters* Speaker Guide
* Frequently Asked Questions* Registration __
* Who Can Attend
* Apply or Register to Attend * Affiliated and Proximate Activities * Guide for User Experience * For CROI Registrants * Frequently Asked Questions* Scholarships __
* New Investigator Scholarship * International Investigator Scholarship * Community Scholarship * Frequently Asked Questions* Resources __
* CROI 2021 Resources* Agenda
* Continuing Medical Education (CME) * Resources From Prior Years* Webcasts
* Abstracts and ePoster Archive * CROI Issues of _TAM_™* Media __
* Media Accreditation and Registration* Policies
* Embargo And Press Release Policies* About CROI __
* CROI Foundation
* Scientific Program Committee * Community Liaison Subcommittee* IAS-USA
* Important Dates and Deadlines * Website Policies and Copyright* Contact Us
* Presenters __
* Abstract Submission * CROI 2021 Abstract Categories * Oral Abstract Presenters * Themed Discussion Presenters* Poster Presenters
* Invited Presenters * Affiliated and Proximate Activities* Session Types
* Frequently Asked Questions* Registration __
* Apply to Attend
* Venue Information
* Travel and Accommodations * Letter Of Invitation * Authorization To Use Government Per Diem Rate * Frequently Asked Questions* Scholarships __
* General Scholarship Information * New Investigator Scholarship * International Investigator Scholarship * Community Scholarship * Frequently Asked Questions* Resources __
* CURRENT CROI__
* Agenda for virtual CROI, March 6-10, 2021* CROI Program
* CROI News
* Mobile App
* Continuing Medical Education (CME)* PRIOR CROI__
* Resources From Prior Years* Webcasts
* CROI Issues of TAMTM * Abstracts and ePoster Archive* Media __
* CROI 2019 Media Highlights* Press Conference
* Media Accreditation and Registration * Embargo And Press Release Policies * Frequently Asked Questions__Login
Search: __
__Login
Search: __
2021 Access the Conference WebcastsCROI
CROI 2022
CROI 2022 will be held on February 13-16, in Denver, Colorado. Additional information will be posted here.View Details
CROI 2021 MARTIN DELANEY PRESENTATION Vaccine Nationalism is Killing Us: How Inequities in Research andAccess
to SARS-CoV-2 Vaccines Will Perpetuate the Pandemic View the Presentation RESOURCES FROM CROI 2021 Abstract eBook, Program, and other resources from _v_CROI 2021.Learn More
NEWS AND ANNOUNCEMENTS NOW AVAILABLE! IAS–USA RELEASED 2 NEW E-PUBLICATION MANUSCRIPTS OF CROI REVIEW ARTICLES. You can find these new articles in Topics in Antiviral Medicine April/May 2021, Volume 29, Issue 2.…Read More__
ACCESS TO VCROI 2021 CONFERENCE MATERIALS In response to community requests, and in a desire to make the full scientific information and discourse…Read More__
REMINDER TO CLAIM CME CREDITS FOR VCROI 2021 The deadline to claim CME credits, ABIM MOC points, or a certificate of participation is Wednesday, May…Read More__
NEW CROI 2021 REVIEW ARTICLE AVAILABLE FROM TOPICS IN ANTIVIRALMEDICINE™
An early e-publication article summarizing key data on new research in complications related to HIV, SARS-CoV-2, and…Read More__
More CROI News
* About CROI
* Presenters
* Registration
* Scholarships
* Resources
* Media
Conference Organizers: IAS-USA Address: 131 Steuart Street, Suite 500, San Francisco, CA 94105 | Office: 415-544-9400 __Facebook __Twitter__Linkedin
The Annual Conference The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases. The CROI Foundation partners with the International Antiviral Society–USA (IAS–USA) for organization of the conference. Copyright © 2021 CROI Foundation/IAS-USA. All Rights Reserved. Website by Enthusiast, Inc.Go to Top
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0